Javascript must be enabled to continue!
Management and long-term consequences of portal vein thrombosis after liver transplantation in children
View through CrossRef
Portal vein thrombosis (PVT) occurs in ≤12% of pediatric recipients of liver transplantation (LT). Known complications of PVT include portal hypertension, allograft loss, and mortality. The management of PVT is varied. A single-center, case-control study of pediatric LT recipients with portal vein (PV) changes after LT was performed. Cases were categorized as early PVT (if PVT was detected within 30 days of transplantation) or late PVT (if PVT was detected more than 30 days after transplantation or if early PVT persisted beyond 30 days). Two non-PVT control patients were matched on the basis of the recipient weight, transplant indication, and allograft type to each patient with PVT. Thirty-two of the 415 LT recipients (7.7%) received 37 allografts and developed PVT. In comparison with control patients, a higher proportion of patients with PVT had PVT present before LT (13.3% versus 0%, P = 0.01). Patients with early PVT usually returned to the operating room, and 9 of 15 patients (60%) had PV flow restored. Patients with late PVT had lower white blood cell (4.9 [1000/μL] versus 6.8 [1000/μL], P < 0.01) and platelet counts (140 [1000/μL] versus 259 [1000/μL], P < 0.01), an elevated international normalized ratio (1.2 versus 1.0, P < 0.001), and more gastrointestinal bleeding (25% versus 8.3%, P = 0.03) compared to controls. Patients with PVT were also less frequently at the expected grade level (52% versus 88%, P < 0.001). The patient survival rates were 84%, 78%, and 78% and 91%, 84%, and 79% for cases and controls at 1, 5, and 10 years, respectively. The allograft survival rates were 90%, 80%, and 80% for cases and 94%, 89%, and 87% for controls at 1, 5, and 10 years, respectively. In conclusion, patients with early and late PVT had preserved allograft function, and there was no impact on mortality. Patients diagnosed with early PVT often underwent operative interventions with successful restoration of flow. Patients diagnosed with late PVT experienced variceal bleeding, and some required portosystemic shunting procedures. Academic delays were also more common. In late PVT, the clinical presentation dictates care because the optimal management algorithm has not yet been determined. Multi-institutional studies are needed to confirm these findings and improve patient outcomes.
Ovid Technologies (Wolters Kluwer Health)
Title: Management and long-term consequences of portal vein thrombosis after liver transplantation in children
Description:
Portal vein thrombosis (PVT) occurs in ≤12% of pediatric recipients of liver transplantation (LT).
Known complications of PVT include portal hypertension, allograft loss, and mortality.
The management of PVT is varied.
A single-center, case-control study of pediatric LT recipients with portal vein (PV) changes after LT was performed.
Cases were categorized as early PVT (if PVT was detected within 30 days of transplantation) or late PVT (if PVT was detected more than 30 days after transplantation or if early PVT persisted beyond 30 days).
Two non-PVT control patients were matched on the basis of the recipient weight, transplant indication, and allograft type to each patient with PVT.
Thirty-two of the 415 LT recipients (7.
7%) received 37 allografts and developed PVT.
In comparison with control patients, a higher proportion of patients with PVT had PVT present before LT (13.
3% versus 0%, P = 0.
01).
Patients with early PVT usually returned to the operating room, and 9 of 15 patients (60%) had PV flow restored.
Patients with late PVT had lower white blood cell (4.
9 [1000/μL] versus 6.
8 [1000/μL], P < 0.
01) and platelet counts (140 [1000/μL] versus 259 [1000/μL], P < 0.
01), an elevated international normalized ratio (1.
2 versus 1.
0, P < 0.
001), and more gastrointestinal bleeding (25% versus 8.
3%, P = 0.
03) compared to controls.
Patients with PVT were also less frequently at the expected grade level (52% versus 88%, P < 0.
001).
The patient survival rates were 84%, 78%, and 78% and 91%, 84%, and 79% for cases and controls at 1, 5, and 10 years, respectively.
The allograft survival rates were 90%, 80%, and 80% for cases and 94%, 89%, and 87% for controls at 1, 5, and 10 years, respectively.
In conclusion, patients with early and late PVT had preserved allograft function, and there was no impact on mortality.
Patients diagnosed with early PVT often underwent operative interventions with successful restoration of flow.
Patients diagnosed with late PVT experienced variceal bleeding, and some required portosystemic shunting procedures.
Academic delays were also more common.
In late PVT, the clinical presentation dictates care because the optimal management algorithm has not yet been determined.
Multi-institutional studies are needed to confirm these findings and improve patient outcomes.
Related Results
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Reduction of the Recipient Spleen Size After Living Donor Liver Transplantation A Retrospective Study.
Reduction of the Recipient Spleen Size After Living Donor Liver Transplantation A Retrospective Study.
Abstract
Background: Liver transplantation is considered an important solution to patients with end stage liver disease and a glimpse of hope for some patients with terribl...
Reduction of Recipient Spleen Size after Living Donor Liver Transplantation: A Retrospective Study
Reduction of Recipient Spleen Size after Living Donor Liver Transplantation: A Retrospective Study
Abstract
Background
Liver transplantation is considered an important solution to patients with end stage liver disease and a gli...
Portal Vein Invasion Secondary to Hepatic Hydatid Disease: A Rare Case Report
Portal Vein Invasion Secondary to Hepatic Hydatid Disease: A Rare Case Report
Background
Hydatid cyst disease is a zoonotic parasitic infection caused by
Echinococcus
spec...
The Prevalence of JAK2 Mutation in High-Altitude Patients with Unprovoked Thrombosis and Thrombosis at Unusual Sites
The Prevalence of JAK2 Mutation in High-Altitude Patients with Unprovoked Thrombosis and Thrombosis at Unusual Sites
Introduction
Thrombosis, both arterial and venous, is a major source of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs). Thrombosis can ...
Venous Thromboembolism in Denmark: Seasonality in Occurrence and Mortality
Venous Thromboembolism in Denmark: Seasonality in Occurrence and Mortality
Background Many cardiovascular conditions exhibit seasonality in occurrence and mortality, but little is known about the seasonality of venous thromboembolism.
Methods ...
Non-Cirrhotic Splanchnic Vein Thrombosis: When Is Anticoagulation Enough?
Non-Cirrhotic Splanchnic Vein Thrombosis: When Is Anticoagulation Enough?
Abstract
Abstract 3390
Background:
In the absence of primary liver disease, thrombosis of the splanchnic vessels ...

